The use of Clofazimine in special populations requires adjusting the dosage or monitoring plan according to physiological conditions, and pregnant women, children, and other groups need to pay special attention to potential risks. The following are specific medication guidelines:

1. Medication for pregnant women

(1) The safety data during pregnancy is limited, and animal experiments have shown embryotoxicity.

(2) Only use when the therapeutic benefits outweigh the risks, and strict medical monitoring is required.

2. Breastfeeding women

(1) Medications can be secreted through breast milk and may cause skin staining in infants.

(2) It is recommended to suspend breastfeeding during treatment or decide based on risk benefit assessment.

3. Medication for children

(1) Children under 5 years old lack systematic research data.

(2) When used for leprosy, the dosage should be accurately calculated based on body weight and growth indicators should be closely monitored.

4. Medication for the elderly

(1) Patients with decreased liver function need to reduce their dosage by 25% -50%.

(2) More prone to gastrointestinal reactions, it is recommended to administer medication in divided doses.

5. Liver dysfunction

(1) When the damage is moderate (Child Pugh B grade), the dose is halved.

(2) Severe damage (Child Pugh C grade) is contraindicated as it may worsen cholestasis.

6. Renal insufficiency

(1) Mild to moderate damage does not require dose adjustment.

(2) Patients with end-stage renal disease need to monitor blood drug concentrations to avoid drug accumulation.

7. Other special groups

(1) G6PD deficiency patients: may induce hemolytic anemia, and should be used with caution.

(2) Patients with a history of intestinal obstruction: contraindicated, may worsen abdominal symptoms.